Does Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics (NRIX)?

Simply Wall St.11-08

Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milestone or royalty income from this asset. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681846079?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-08 09:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681846079","market":"hk","top_or_hot":-1,"title":"Does Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics (NRIX)?","media":"Simply Wall St.","content":"<div>\n<p>Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milestone or royalty income from this asset. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-phase-1-drug-cancellation-change-the-bull-case-for-nuri\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Does Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics (NRIX)?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDoes Phase 1 Drug Cancellation Change The Bull Case For Nurix Therapeutics (NRIX)?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-08 09:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-phase-1-drug-cancellation-change-the-bull-case-for-nuri><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milestone or royalty income from this asset. ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-phase-1-drug-cancellation-change-the-bull-case-for-nuri\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRIX","symbol_name":"Nurix Therapeutics","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-phase-1-drug-cancellation-change-the-bull-case-for-nuri","article_id":"2681846079","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/does-phase-1-drug-cancellation-change-the-bull-case-for-nuri","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681846079","pubTimestamp":1794101394,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"SSasha JovanovicNovember 8, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRIX":"Nurix Therapeutics","BK4139":"生物科技"},"translate_title":"1期药物取消会改变Nurix Therapeutics（NRIX）的牛市吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRIX":1.5},"content_text":"Sanofi informed Nurix Therapeutics that it has discontinued the Phase 1 trial of SAR448272 and terminated the STAT6 degrader program, removing any future milestone or royalty income from this asset. The end of SAR448272 shifts the economic weight of Nurix Therapeutics' pharma partnerships toward remaining Sanofi licensed programs and other collaborators, increasing reliance on how those pipelines progress. We will now look at how Nurix Therapeutics' investment narrative could shift as Sanofi walks away from the SAR448272 program.  Benchmark your thesis on Nurix Therapeutics against other potential opportunities by scanning our curated list of 19 high quality undiscovered gems with similar under-the-radar partnership stories and risk profiles. AdvertisementNurix Therapeutics Investment Narrative Recap To own Nurix Therapeutics, you have to believe the degrader platform and partnered pipeline can offset lumpier collaboration income and high R&D spend over time. The loss of SAR448272 removes a potential stream of future Sanofi milestones and royalties, which tightens the focus on how bexobrutideg and IRAK4 progress. In the near term, the clearest catalyst is execution with Roche on bexobrutideg across oncology and autoimmune indications. The biggest operational risk remains that larger studies fail to echo early response rates or that external funding and partnership flows do not adequately cover ongoing operating losses if one time payments soften. The Roche bexobrutideg partnership now matters even more in light of Sanofi stepping away from SAR448272. That alliance includes a US$700 million upfront payment, up to US$2.3 billion in milestones, a 50:50 U.S. cost and profit share, and ex U.S. royalties that can partially offset lost optionality from Sanofi on STAT6. For shareholders, execution around the broad bexobrutideg development plan in CLL, lymphoma, chronic spontaneous urticaria and multiple sclerosis is the practical swing factor. Trial momentum, the timing of any further Roche related receipts and progress with the Gilead partnered IRAK4 degrader now carry more weight in Nurix Therapeutics' story. Nurix Therapeutics' narrative projects US$297.9 million in revenue and US$47.6 million in earnings by 2029. This assumes revenue decreases by 24.9% per year and earnings decline by about US$247.3 million from US$294.9 million today. Uncover why Nurix Therapeutics' fair value indicates a 125% potential upside to its current price that could narrow quickly. NasdaqGM:NRIX 1-Year Stock Price Chart Exploring Other Perspectives Some of the most optimistic analysts focused on STAT6 as a key upside catalyst for Nurix Therapeutics, with forecasts before this Sanofi decision that revenues could reach about US$466.0 million and earnings about US$8.2 million by 2029. You now have fresh information they did not have, so treat those projections as moving targets and compare several viewpoints. Explore 2 other Nurix Therapeutics fair value estimates, including one that suggests as much as 228% upside from the current price! Reach Your Own Conclusion Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider trusting your own analysis.  A great starting point for your Nurix Therapeutics research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. See our latest analysis for Nurix Therapeutics. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.  Looking For More Investment Ideas Beyond Nurix Therapeutics? Once you have a handle on Nurix Therapeutics, it can help to widen the lens and compare it with other companies that share similar risk and reward trade offs. The Simply Wall St Screener lets you quickly surface different types of opportunities that might better match your time horizon, volatility comfort, or focus on quality.  If you want potential upside with tighter risk controls, start by reviewing a 29 resilient stocks with low risk scores that score well on resilience and business stability. For investors who care most about balance sheet strength and fundamental robustness, filter for companies in the list of solid balance sheet and fundamentals (24 results) to see businesses with cleaner finances. If you enjoy finding earlier stage opportunities before they gain wider attention, scan the 9 elite penny stocks with strong financials that pair smaller market values with more robust financial profiles.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Nurix Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681846079","isCrawlerRequest":true}